|
|
||||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the Department of Pediatrics (Drs. Yaari, Yafe-Zimerman, Schwartz, Branski, and Kerem) and Unit of Pediatric Respiratory Medicine (Dr. Kerem), Shaare Zedek Medical Center, Jerusalem, Israel; Department of Epidemiology (Dr. Slater), Israel Ministry of Health, Jerusalem, Israel; Department of Family Medicine (Dr. Shvartzman), Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel; and Government Central Laboratories (Dr. Andoren), Israel Ministry of Health, Jerusalem, Israel.
Correspondence to: Eitan Kerem, MD, Pediatric Respiratory Medicine, Shaare Zedek Medical Center, PO Box 3235, Jerusalem 91031, Israel; e-mail: ek{at}cc.huji.ac.il
| Abstract |
|---|
|
|
|---|
Design: Retrospective study.
Subjects: Children and young adults who were reported by local physicians to the Department of Epidemiology in the Israeli Ministry of Health with serologically confirmed pertussis and who were immunized previously were included. Information sought included personal data, epidemiologic data, signs and symptoms, laboratory results, initial diagnosis, and treatment.
Results: In the 95 previously immunized patients with serologically confirmed pertussis (mean age [± SD], 8.9 ± 4.4 years old; range, 5 to 30 years old), the mean duration from onset of symptoms until the final diagnosis of pertussis was 23 ± 15 days. The disease was usually atypical and generally mild. All the described patients had cough, usually prolonged, lasting 4 ± 3.6 weeks. Only 6% had the classic whoop. The mean WBC count was 8.7 ± 2.6 cells/mm6, and the lymphocyte count was 40 ± 12%. Two patients were admitted to the hospital for severe pneumonia. Among the reported cases, the proportion of patients between the ages of 10 and 45 years increased from 6.5% during the period from 1971 to 1980, to 26% during the period from 1980 to 1990, and to 38% during a 1989 outbreak.
Conclusions: Pertussis in previously immunized individuals is usually characterized by an atypical and relatively mild clinical course. Patients suffer mainly from a prolonged and persistent cough. Early diagnosis may lead to prompt administration of therapy. Prophylaxis of exposed persons might be effective in decreasing both severity and transmission of the disease.
Key Words: pertussis, clinical course pertussis, epidemiology pertussis, immunization
| Introduction |
|---|
|
|
|---|
The period of immunity induced by the pertussis vaccine tends to wane within 5 to 10 years and is shorter than that induced by the disease itself.17 Although the number of susceptible adults is increasing, it is difficult to determine the true incidence of pertussis in adults. Studies of adults with prolonged cough have found that 20 to 25% have serologic evidence of recent pertussis infection.11 12 13 14 18 19 20 However, adults may have an atypical presentation of pertussis with a modified clinical course.18 19 20 Because the signs and symptoms are usually nonspecific, pertussis is rarely considered in adults. This may lead to underdiagnosis and lack of, or a delay in, treatment. Furthermore, in vaccinated populations, adults maintain the ability to transmit B pertussis and are now the primary source of infection to susceptible children who may develop severe disease. Several studies on a small number of adult patients with pertussis reported the association between pertussis and chronic cough. However, to the best of our knowledge, the disease in previously immunized children and adults was documented in a limited number of patients. Therefore, the aim of this study was to investigate the clinical presentation and the course of the disease in previously immunized patients suffering from B pertussis infection.
| Materials and Methods |
|---|
|
|
|---|
In all cases, the Pertussis Laboratory of the Ministry of Health
Central Laboratories confirmed the diagnosis of pertussis. For the
purpose of this study, serologic confirmation of pertussis required an
agglutination titer
1:640, or a fourfold rise in
agglutination titers obtained 2 to 3 weeks apart, or positive pertussis
IgM levels determined by enzyme-linked immunosorbent assay
method.21
As cutoff, negative, and positive control, we
used in-house standards calibrated by using a pertussis kit (Virotech
GmbH; Russelsheim, Germany). Cultures were not taken.
The reporting physicians were contacted and asked to complete a questionnaire based on the patient's medical records. Information sought included personal data, epidemiologic data, signs and symptoms, laboratory results, initial diagnosis, treatment, and complications.
| Results |
|---|
|
|
|---|
Of the 1,091 cases reported between the years 1971 and 1980, the percentage of cases in the group aged 10 to 45 years was 6.5%. This figure increased during the next decade to 26% of the 754 reported cases. In 1989, 38% of the 219 reported cases occurred among individuals between the ages of 10 and 45 years.
Of the 552 cases of pertussis reported to the Ministry of Health from January 1986 to December 1991, 283 were children and young adults between the ages of 5 and 30 years (mean age, 10.4 ± 4.3 years old; median, 10 years old). Only 180 patients completed pertussis vaccination during childhood (63%). Clinical information was available for 95 individuals (39% were male) aged 5 to 30 years (mean age, 8.9 ± 4.4 years old; median, 9 years old). Seventy patients were 5 to 10 years old, 16 were 11 to 14 years old, and 9 were 15 to 30 years old. In 66% of these 95 patients, a history of contact with other individuals with pertussis was documented.
The mean duration from onset of symptoms until the final diagnosis of pertussis was 23 ± 15 days (range, 7 to 90 days; median, 14 days). In 46% of the cases, pertussis was the initial diagnosis; most of the patients who developed the disease were diagnosed in a small kibbutz community during a pertussis outbreak after the diagnosis of a first case. Various incorrect diagnoses were ascribed until the diagnosis of pertussis was established. Mycoplasma pneumoniae infection was the most common initial diagnosis (17%). Other initial diagnoses included sinusitis (7%), upper respiratory tract infection (4%), asthma (4%), laryngitis (3%), and suspected cystic fibrosis (1%).
Table 1 shows the frequency of symptoms in the 95 vaccinated patients with serologically confirmed pertussis. The disease in these patients was atypical, because the clinical course was generally mild. All the described patients had cough, usually prolonged, lasting 4 ± 3.6 weeks (range, 1 to 24 weeks; median 3 weeks). The cough was productive in 7% of the patients, whereas the rest had a dry cough; only 6% had the classic whoop. Of the patients, 13% had temperature > 37.5°C. Five of the patients visited an emergency department due to severe cough and dyspnea. Two required hospitalization: a 5-year-old girl with hypoxemia and a 10-year-old boy who developed secondary pneumonia with a small pleural effusion (pleurocentesis was not performed).
|
Sixty-eight patients (71%) received antibiotic therapy before the diagnosis of pertussis was made. The majority (78% of treated patients) received erythromycin, while others were treated with penicillin, amoxicillin, or doxycycline. In most patients there was no apparent clinical improvement with antibiotic therapy.
| Discussion |
|---|
|
|
|---|
Pertussis is much more common in adults than previously believed. In Israel, the proportion of adolescents and young adults among the reported pertussis cases increased dramatically from 6.5% from 1971 to 1980 to 26% from 1980 to 1990 and 38% during the 1989 outbreak. This trend is similar to that reported by the Centers for Disease Control and Prevention in the United States,24 which found that the proportion of pertussis cases occurring in patients > 10 years old increased from 15% from 1977 to 1978 to 28% during the time from 1992 to 1994. Before the vaccination era, the majority of pertussis cases occurred among infants. At that time, most of the population was exposed to pertussis and acquired natural immunity during the first years of life. Subsequent exposure to other infants and young children with pertussis served to boost immunity. However, the immunity induced by the whole-cell vaccination is shorter than the immunity induced by the disease itself, and tends to wane within 5 to 10 years.17 Thus, several decades after the introduction of the pertussis vaccine, many adults became susceptible to pertussis. Although the vaccine has been very effective in controlling the disease, the transmission of B pertussis has not been eliminated by vaccination and still causes morbidity, even in the vaccinated population.25 The 1993 pertussis outbreak in Cincinnati6 occurred primarily among immunized children, demonstrating that the vaccine did not give full protection against the disease. It is now appreciated that adults are a major reservoir for the spread of the infection to infants.15 16 20 Pertussis was also isolated from adults infected with HIV who complained of persistent cough.26
Yet, many physicians are unaware that adults may themselves develop pertussis.27 This, in addition to the nonspecific or relative lack of symptoms among adults with pertussis, has led to under-recognition of the disease in this age category.18
The only typical finding of pertussis in our study was a prolonged and disturbing cough that lasted from several weeks to several months. Only 5% had whoop. Similarly, Wright et al12 reported that cough was found in > 85% of the immunized adults with pertussis. Whoop and lymphocytosis were not observed. Prospective studies suggested that 20 to 25% of adults with persistent cough might have pertussis.3 19 Therefore, epidemiologic studies are needed to determine the incidence of pertussis in adults with respiratory illness.
In our study, the duration of time until the final diagnosis was 23 ± 15 days. This delay in diagnosis may be critical, because initiation of therapy after 3 weeks will not shorten the course of the disease or prevent its spread.28 Early diagnosis of pertussis relies on clinical suspicion, and the definitive diagnosis of pertussis relies on laboratory tests. Cultures are difficult to obtain and need to be taken early in the course of the disease.29 The percentage of positive cultures changes precipitously from 67 to 81% shortly after exposure to 25%, 14%, and 0% during the 3rd, 4th, and 5th weeks, respectively. Compared with cultures, direct fluorescent antigen detection is not more sensitive, and it is much less specific. Determination of antibody titer IgA and IgG to lymphocytosis promoting factor, filamentous hemagglutinin, and agglutinogens (antibodies against various virulent factors of B pertussis) is currently the most sensitive diagnostic test.29 30 Polymerase chain reaction, using a specific probe for B pertussis, may offer an early diagnosis of pertussis with high specificity and sensitivity.31 32 33
Pertussis in immunized children and young adults may be associated with morbidity. Five percent of the patients in our study visited an emergency department, and 2% were hospitalized. In addition, many patients had unnecessary and costly diagnostic evaluations and may have suffered from anxiety because of the undiagnosed chronic and protracted cough. Patients may experience loss of time from work or school due to the persistent cough of pertussis. Although the clinical presentation in immunized children and young adults is atypical and the course is usually benign, as shown in our study, pertussis may still cause morbidity.
In conclusion, pertussis should be considered in the differential diagnosis of persistent cough in previously immunized children and adults. Given the relative unavailability of accurate diagnostic tests and the usual absence of whoop or lymphocytosis, a recommendation for prompt administration of erythromycin in patients presenting with persistent cough and the prophylaxis of exposed persons before culture or serologic results are available should be considered. This would be effective in decreasing both disease severity and transmission of B pertussis.34 Because pertussis is not a life-threatening illness in adults, pertussis vaccination is not currently recommended in persons > 6 years of age. However, the availability of the less reactogenic acellular vaccine may allow booster immunization and should be thoughtfully considered.
Received for publication May 12, 1998. Accepted for publication December 3, 1998.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
S. Schafer, H. Gillette, K. Hedberg, and P. Cieslak A Community-wide Pertussis Outbreak: An Argument for Universal Booster Vaccination. Arch Intern Med, June 26, 2006; 166(12): 1317 - 1321. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E. Tozzi, L. Pastore Celentano, M. L. Ciofi degli Atti, and S. Salmaso Diagnosis and management of pertussis Can. Med. Assoc. J., February 15, 2005; 172(4): 509 - 515. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E. Tozzi, L. Rava, M. L. Ciofi degli Atti, S. Salmaso, and the Progetto Pertosse Working Group Clinical Presentation of Pertussis in Unvaccinated and Vaccinated Children in the First Six Years of Life Pediatrics, November 1, 2003; 112(5): 1069 - 1075. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. S. Irwin and J. M. Madison The Diagnosis and Treatment of Cough N. Engl. J. Med., December 7, 2000; 343(23): 1715 - 1721. [Full Text] [PDF] |
||||
![]() |
Atypical Presentation of Pertussis Journal Watch (General), June 4, 1999; 1999(604): 5 - 5. [Full Text] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |